Zacks: Brokerages Anticipate LeMaitre Vascular Inc (LMAT) to Announce $0.20 Earnings Per Share
Equities analysts expect LeMaitre Vascular Inc (NASDAQ:LMAT) to report earnings of $0.20 per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for LeMaitre Vascular’s earnings. The highest EPS estimate is $0.24 and the lowest is $0.18. LeMaitre Vascular reported earnings of $0.21 per share during the same quarter last year, which indicates a negative year over year growth rate of 4.8%. The firm is scheduled to report its next quarterly earnings results on Wednesday, February 20th.
According to Zacks, analysts expect that LeMaitre Vascular will report full-year earnings of $1.03 per share for the current fiscal year, with EPS estimates ranging from $1.02 to $1.06. For the next year, analysts expect that the firm will post earnings of $0.94 per share, with EPS estimates ranging from $0.88 to $0.99. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for LeMaitre Vascular.
LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Friday, October 5th. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.21. The company had revenue of $24.17 million for the quarter, compared to analyst estimates of $26.06 million. LeMaitre Vascular had a net margin of 21.09% and a return on equity of 19.49%.
In other LeMaitre Vascular news, Chairman George W. Lemaitre sold 39,820 shares of the company’s stock in a transaction that occurred on Friday, July 27th. The shares were sold at an average price of $37.34, for a total value of $1,486,878.80. Following the completion of the sale, the chairman now owns 3,085,291 shares of the company’s stock, valued at $115,204,765.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David B. Roberts sold 21,005 shares of the company’s stock in a transaction that occurred on Thursday, August 2nd. The shares were sold at an average price of $35.72, for a total transaction of $750,298.60. Following the completion of the sale, the director now directly owns 5,373 shares of the company’s stock, valued at approximately $191,923.56. The disclosure for this sale can be found here. Insiders sold 97,506 shares of company stock valued at $3,608,759 in the last ninety days. Insiders own 20.30% of the company’s stock.
Large investors have recently modified their holdings of the business. Piedmont Investment Advisors LLC bought a new stake in LeMaitre Vascular in the second quarter valued at approximately $119,000. Tower Research Capital LLC TRC increased its stake in LeMaitre Vascular by 222.8% in the second quarter. Tower Research Capital LLC TRC now owns 4,451 shares of the medical instruments supplier’s stock valued at $149,000 after purchasing an additional 3,072 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in LeMaitre Vascular in the first quarter valued at approximately $215,000. Jane Street Group LLC bought a new stake in LeMaitre Vascular in the second quarter valued at approximately $206,000. Finally, Creative Planning bought a new stake in LeMaitre Vascular in the second quarter valued at approximately $220,000. 79.75% of the stock is owned by hedge funds and other institutional investors.
Shares of LMAT traded up $0.29 on Friday, reaching $28.22. 222,174 shares of the company’s stock were exchanged, compared to its average volume of 151,980. The company has a market cap of $748.16 million, a price-to-earnings ratio of 32.81, a price-to-earnings-growth ratio of 2.42 and a beta of 0.63. LeMaitre Vascular has a 12 month low of $26.45 and a 12 month high of $41.28.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 6th. Investors of record on Tuesday, November 20th will be paid a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.99%. The ex-dividend date of this dividend is Monday, November 19th. LeMaitre Vascular’s dividend payout ratio (DPR) is 32.56%.
About LeMaitre Vascular
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Further Reading: Understanding Stock Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.